key: cord-0829007-p8ahuyxb authors: Ibrahimagić, Omer Ć.; Smajlović, Dževdet; Dostović, Zikrija; Kunić, Suljo; Šehanović, Aida; Kojić, Biljana title: COMMENT ON AN ARTICLE: „Coagulopathy in COVID‐19“ date: 2020-10-08 journal: J Thromb Haemost DOI: 10.1111/jth.15122 sha: e5314ba91d7f9aed918e374c142d290cea5ef857 doc_id: 829007 cord_uid: p8ahuyxb We have read with great attention the article „Coagulopathy in COVID‐19“ written by Toshiaki Iba et al. (Authors), published in the September issue of Journal (1). The Authors performed an effective and informative review. Nevertheless, we welcome the opportunity to make a short comment as well. This very interesting article evaluates current literature regarding harmful hypercoagulable milieu of COVID‐19. Surprisingly, we can not see that the Authors recommended other diagnostic considerations such a checking for hyperhomocysteinemia in patients with COVID‐19. Undoubtedly, hyperhomocysteinemia has neurotoxic, neuroinflammatory, neurodegenerative, prooxidative, as well as proatherogenic/ prothrombotic effects. This article is protected by copyright. All rights reserved We have read with great attention the article "Coagulopathy in COVID-19" written by Toshiaki Undoubtedly, hyperhomocysteinemia has neurotoxic, neuroinflammatory, neurodegenerative, prooxidative, as well as proatherogenic/ prothrombotic effects. 2 Also, recent evidence introduces the role of hyperhomocysteinemia as a strong risk factor for thromboembolism, given its influence in platelet reactivity. 3, 4 In our opinion, it is very important to plan that finding because the novelty pandemic disease has yet unclear kaleidoscopic presentation. Unfortunately, according to PubMed survey, there was very poor reliable data due to concomitance of hyperhomocysteinemia and pulmonary embolism in COVID-19 patients. This article is protected by copyright. All rights reserved Herein, as a consequence of SARS-CoV-2 infection, high number of pulmonary embolism was noted in COVID-19 pneumonia patients (20.6-28%), despite the fact that 90% of them were receiving prophylactic antithrombotic treatment according to the current guidelines. 5, 6 Interestingly, according to studies of Yang et al 7 as well as Ponti, Ruini and Tomasi 8 on 273 and 40 COVID-19 patients, levels of homocysteine were significantly higher and showed predictive value for CT-imaging progressions in pulmonary embolism. In this setting, hyperhomocysteinemia may be also predisposing but not well recognize risk factor for vascular accidents in coagulopathic state of COVID-19. Hopefully, values of folic acid (B9 vitamin) and B12 vitamin are in negative correlation with levels of homocysteine. 9 Furthermore, B vitamins are enhancers of the immune system. 10 Our studies from Bosnia and Herzegovina showed that the intake of folic acid, sometimes with B12 vitamin as well, was efficient in creating normalized homocysteine levels in older patients with ishemic stroke and Parkinson's disease. 11, 12 Despite knowledge gaps and lack of randomized controlled trials, there is an urgent need to This article is protected by copyright. All rights reserved medication of second echelon in the treatment of unhidden COVID-19 hyperhomocysteinemia. In conclusion, we emphasize that further studies will show harmful potential of hyperhomocysteinemia on pulmonary embolism in COVID-19 patients as well as benefitial therapeutic add-on effects of various B-vitamins. This report received no specific grant from any funding agency in the public, commercial, or not for profit sectors. Coagulopathy in COVID-19 Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses Homocysteine levels and platelet reactivity in coronary artery disease treated with ticagrelor Polymorphisms C667T and A1298C of MTHFR gene: Homocysteine levels and prothrombotic biomarkers in coronary and pulmonary 1076029618780344 Lille Haemostasis COVID-19 Group. Pulmonary embolism in COVID-19 patients: Awareness of an increased prevalence Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19 Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective Hyperhomocysteinemia and its treatment in patients with ischemic stroke Hyperhomocysteinemia and its treatment in patients with Parkinson's disease Accepted Article All authors declare that there is no conflict of interest.